CD19 and acute lymphoblastic leukemia: Gardner et al. [145] found that the EI strategy with tocilizumab and/or corticosteroids could reduce the incidence of severe CRS in ALL patients receiving CD19 CAR T-cells without dampening the antitumor efficacy.